Clinical Trials in Melbourne, Victoria
678 recruiting
Showing 1–20 of 527 trials
Recruiting
Phase 3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
HR+/HER2- Breast Cancer
BeOne Medicines1,056 enrolled13 locationsNCT07492641
Recruiting
Phase 1
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
TRex Bio, Inc.115 enrolled15 locationsNCT06934252
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ovarian Cancer
AbbVie400 enrolled73 locationsNCT07059845
Recruiting
Phase 4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Multiple Myeloma
Pfizer80 enrolled33 locationsNCT06057402
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Phase 1Phase 2
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Gastrointestinal Cancer
Merck Sharp & Dohme LLC180 enrolled62 locationsNCT06596694
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled263 locationsNCT06717347
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled26 locationsNCT04643002
Recruiting
Phase 1Phase 2
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Paroxysmal Nocturnal Hemoglobinuria, PNH
ADARx Pharmaceuticals, Inc.50 enrolled4 locationsNCT05876312
Recruiting
Phase 3
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
CandidemiaCandidiasis, Invasive
Basilea Pharmaceutica450 enrolled143 locationsNCT05421858
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled183 locationsNCT07060807
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-small Cell Lung Cancer
Hoffmann-La Roche320 enrolled71 locationsNCT05789082
Recruiting
Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie380 enrolled166 locationsNCT06158841
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled286 locationsNCT06925737
Recruiting
Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled499 locationsNCT06430801
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC868 enrolled229 locationsNCT06077760
Recruiting
Phase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Sanofi208 enrolled79 locationsNCT07170917
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda171 enrolled114 locationsNCT06722235